ALS-FTD Overlap: Mechanistic Pathways

ALS-FTD Overlap: Mechanistic Pathways

Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent a disease continuum with overlapping clinical, genetic, and pathological features. Approximately 50% of ALS patients develop cognitive or behavioral impairment, while 10-15% of FTD patients exhibit motor neuron disease features. This clinical overlap reflects shared underlying pathogenic mechanisms that converge on RNA metabolism dysfunction, proteostasis failure, and nucleocytoplasmic transport defects. This pathway page synthesizes the mechanistic basis for ALS-FTD overlap, providing a unified model that integrates the major genetic and molecular drivers of both conditions. [@ringholz2005] [@strong2017]

The ALS-FTD Spectrum

Clinical Continuum

The clinical presentation of ALS-FTD ranges across a spectrum from pure ALS to pure FTD, with intermediate phenotypes including:

• ALS-only: Progressive muscle weakness without significant cognitive impairment
• ALS-FTD: Combined motor neuron disease with frontotemporal cognitive/behavioral changes
• FTD-ALS: Predominant frontotemporal dementia with subsequent motor neuron signs
• FTD-only: Frontotemporal dementia without motor manifestations

The Strong criteria (2017) formalized this spectrum, classifying patients as cognitively normal (ALS-cn), with impairment (ALS-ci), or with full FTD (ALS-FTD). Approximately 15% of patients meet criteria for ALS-FTD, while subclinical cognitive impairment is present in up to 50% of ALS patients. [@strong2017]

...

ALS-FTD Overlap: Mechanistic Pathways

Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent a disease continuum with overlapping clinical, genetic, and pathological features. Approximately 50% of ALS patients develop cognitive or behavioral impairment, while 10-15% of FTD patients exhibit motor neuron disease features. This clinical overlap reflects shared underlying pathogenic mechanisms that converge on RNA metabolism dysfunction, proteostasis failure, and nucleocytoplasmic transport defects. This pathway page synthesizes the mechanistic basis for ALS-FTD overlap, providing a unified model that integrates the major genetic and molecular drivers of both conditions. [@ringholz2005] [@strong2017]

The ALS-FTD Spectrum

Clinical Continuum

The clinical presentation of ALS-FTD ranges across a spectrum from pure ALS to pure FTD, with intermediate phenotypes including:

• ALS-only: Progressive muscle weakness without significant cognitive impairment
• ALS-FTD: Combined motor neuron disease with frontotemporal cognitive/behavioral changes
• FTD-ALS: Predominant frontotemporal dementia with subsequent motor neuron signs
• FTD-only: Frontotemporal dementia without motor manifestations

The Strong criteria (2017) formalized this spectrum, classifying patients as cognitively normal (ALS-cn), with impairment (ALS-ci), or with full FTD (ALS-FTD). Approximately 15% of patients meet criteria for ALS-FTD, while subclinical cognitive impairment is present in up to 50% of ALS patients. [@strong2017]

Genetic Architecture

At least nine genes cause both ALS and FTD, reflecting shared pathogenic mechanisms:

| Gene | Protein Function | ALS | FTD | Key Mechanism |
|------|-----------------|-----|-----|----------------|
| [C9orf72](/genes/c9orf72) | DENN domain protein | ~40% familial | ~25% familial | Repeat expansion, DPR toxicity |
| [TARDBP](/genes/tardbp) | RNA-binding protein | ~5% familial | ~5% familial | TDP-43 proteinopathy |
| [FUS](/genes/fus) | RNA-binding protein | ~5% familial | ~5% familial | FUS proteinopathy |
| GRN | Progranulin | Rare | ~20% familial | Lysosomal dysfunction |
| TBK1 | Kinase | ~5% familial | ~5% familial | Autophagy, inflammation |
| OPTN | Autophagy receptor | Rare | Rare | Autophagy impairment |
| VCP | AAA ATPase | Rare | Rare | Protein quality control |
| CHCHD10 | Mitochondrial protein | Rare | Rare | Mitochondrial dysfunction |
| TIA1 | Stress granule protein | Rare | Rare | Stress granule dysregulation |

Core Mechanistic Pathways

Pathway 1: C9orf72 Hexanucleotide Repeat Expansion

Genetics and Epidemiology

The GGGGCC hexanucleotide repeat expansion in the first intron of the [C9orf72](/genes/c9orf72) gene is the most common genetic cause of both familial ALS and FTD. Pathological repeats range from 30 to over 1000 units, with repeats >60 showing full penetrance. The expansion is inherited in an autosomal dominant manner, with anticipation (earlier onset in successive generations) observed in some families. [@renton2011] [@decipher2011]

Three Disease Mechanisms

The C9orf72 expansion causes disease through three interconnected mechanisms:

1. RNA Foci Formation

The expanded repeat RNA forms nuclear and cytoplasmic RNA foci that sequester essential RNA-binding proteins:

• Sequestration of TDP-43: Reduces nuclear availability of functional TDP-43
• Splicing factor depletion: hnRNPs, SRSF proteins mislocalized
• RNA processing disruption: Global alterations in RNA metabolism

2. Dipeptide Repeat Protein (DPR) Toxicity

Repeat-associated non-AUG (RAN) translation produces five dipeptide repeat proteins from both sense and antisense transcripts. [@mori2013]

| DPR Species | Translation Direction | Key Properties | Toxicity Mechanism |
|-------------|----------------------|----------------|-------------------|
| Poly-GA | Sense (+1 frame) | Most abundant | Proteasome inhibition, p62 sequestration |
| Poly-GP | Sense (+2 frame) | Less aggregation-prone | Moderate toxicity |
| Poly-GR | Sense (+3 frame) | Arginine-rich | Nucleocytoplasmic transport disruption |
| Poly-PR | Antisense (+2 frame) | Arginine-rich | Nuclear pore binding, highly toxic |
| Poly-PA | Antisense (+1 frame) | Forms nuclear aggregates | Splicing disruption |

Arginine-rich DPRs (poly-GR, poly-PR) are particularly toxic, directly binding to nuclear pore components and disrupting nucleocytoplasmic transport. [@zhang2015]

3. C9orf72 Haploinsufficiency

The expansion reduces C9orf72 expression through repeat-mediated transcriptional interference and epigenetic changes:

• Endolysosomal dysfunction: C9orf72 regulates trafficking to lysosomes
• Autophagy impairment: Loss of normal autophagic flux
• Inflammation: Altered immune cell function

Pathway 2: TDP-43 Proteinopathy

Normal TDP-43 Function

TDP-43 (TAR DNA-binding protein 43) is a 414-amino acid RNA-binding protein encoded by [TARDBP](/genes/tardbp). Normal functions include:

• Alternative splicing regulation: Controls inclusion/exclusion of hundreds of exons
• mRNA stability: Regulates transcript half-life
• Stress response: Localizes to stress granules under cellular stress
• DNA damage response: Participates in genome integrity maintenance

TDP-43 Pathology

The hallmark of TDP-43 proteinopathy is mislocalization from nucleus to cytoplasm, observed in:

• 97% of ALS cases (sporadic and familial)
• 50% of FTD cases (particularly FTLD-TDP type A)
• ~30-50% of Alzheimer's disease cases (LATE co-pathology)

Pathological features include:

Nuclear depletion: Loss of nuclear TDP-43 function

Cytoplasmic aggregation: Formation of inclusions

Hyperphosphorylation: Phosphorylation at Ser409/410

C-terminal fragmentation: 25kDa and 35kDa fragments

TDP-43 and C9orf72 Connection

The C9orf72 expansion causes TDP-43 pathology through:

• RNA foci sequester TDP-43, reducing nuclear availability
• Arginine-rich DPRs disrupt nuclear import machinery
• C9orf72 loss-of-function impairs autophagy of TDP-43 aggregates

Pathway 3: RNA Toxicity

RNA Foci-Mediated Toxicity

RNA foci represent one of the earliest pathogenic events in C9orf72-associated disease:

• Form in neurons before symptom onset
• Sequester essential splicing regulators
• Cause widespread RNA processing defects
• Progress to DPR pathology over time

Splicing Dysregulation

Loss of nuclear RNA-binding protein function leads to:

• Cryptic exon inclusion: Aberrant inclusion of normally repressed exons
• mRNA stability alterations: Dysregulated transcript levels
• Alternative splicing changes: Affects thousands of transcripts

Recent Discoveries

Recent research has identified additional RNA toxicity mechanisms:

• Nuclear speckle disruption: C9orf72 repeats dysregulate splicing through nuclear speckle integrity loss [@nuclear_speckle_2024]
• Poly-GR ribotoxicity: Impairs translation elongation through ribosomal stress pathways [@poly_gr_2024]
• EXOC2 regulation: Exocyst component modulates repeat toxicity

Pathway 4: Nucleocytoplasmic Transport Defects

Mechanisms of Disruption

Multiple disease mechanisms converge on nucleocytoplasmic transport:

Arginine-rich DPRs: Direct binding to nucleoporins (Nup62, Nup153)

Nuclear pore damage: Progressive deterioration of pore complex integrity

Importin sequestration: RNA-binding protein aggregates sequester importins

Exportin dysfunction: RAN translation products interfere with export

Consequences

• Nuclear accumulation of cytoplasmic proteins
• Decreased nuclear import of transcription factors
• Loss of nuclear RNA processing functions
• Cellular dysfunction and death

Pathway 5: Stress Granule Dysregulation

Normal Stress Granule Function

Stress granules are membrane-less organelles that form in response to cellular stress:

• Temporary storage for translationally arrested mRNAs
• Contain RNA-binding proteins including TIA1, G3BP1, TDP-43, FUS
• Dynamic structures that dissolve when stress resolves
• Essential for cellular stress response

Pathological Alterations in ALS-FTD

In ALS-FTD, stress granule dynamics are dysregulated:

• Persistent granules: Failure to dissolve properly
• Sequestration of essential proteins: TIA1, G3BP1, and others trapped
• Transition to aggregates: Granules become irreversible inclusions
• Mutation effects: ALS-causing mutations in TIA1, FUS, TDP-43 alter granule dynamics

Stress Granules as Therapeutic Targets

Stress granules represent a promising therapeutic target:

• Granule dissolution: Promoting disassembly when stress resolves
• Modulating material properties: Preventing liquid-to-solid transition
• Targeting downstream effects: Blocking persistent granule toxicity

Pathway 6: Autophagy Dysfunction

C9orf72 and Autophagy

The C9orf72 protein forms a complex with SMCR8 and WDR41 that regulates:

• Autophagosome formation: Initiation of autophagy
• Lysosomal fusion: Final degradation of cargo
• Endolysosomal trafficking: Cellular waste clearance

Autophagy Impairment in ALS-FTD

Multiple mechanisms cause autophagy dysfunction:

• C9orf72 haploinsufficiency: Loss of normal autophagic function
• TDP-43 aggregation: Overwhelms clearance systems
• DPR toxicity: Impairs autophagic flux
• Genetic modifiers: TBK1, OPTN, VCP mutations affect clearance

Therapeutic Implications

Autophagy enhancement represents a therapeutic strategy:

• Small molecule activators: Rapamycin, trehalose
• Gene therapy: Delivering autophagy-enhancing genes
• Targeting upstream regulators: Modulating signaling pathways

Shared Genetic Risk Factors

Modifier Genes

Several genes modify ALS-FTD risk and progression:

| Gene | Function | Effect |
|------|----------|--------|
| ATXN2 | RNA binding, stress granules | Intermediate repeat expansions increase risk |
| UNC13A | Synaptic transmission | Splicing variants affect survival |
| TFEB | Autophagy regulation | Modulates aggregate clearance |
| TREM2 | Microglial signaling | Affects neuroinflammation |

Epigenetic Factors

DNA methylation and histone modifications at the C9orf72 locus influence:

• Age of onset
• Disease progression rate
• Phenotypic expression (ALS vs FTD)

Therapeutic Implications

Targeting Shared Mechanisms

| Mechanism | Therapeutic Approach | Status |
|-----------|-------------------|--------|
| C9orf72 expansion | ASOs (BIIB060, WVE-004) | Phase 1/2 |
| TDP-43 aggregation | ASOs, small molecules | Preclinical |
| DPR toxicity | RAN translation inhibitors | Preclinical |
| Nucleocytoplasmic transport | Pore stabilizers | Preclinical |
| Stress granules | Granule modulators | Preclinical |
| Autophagy | Enhancement strategies | Clinical trials |

Biomarker Development

Shared mechanisms enable cross-disease biomarkers:

• Neurofilament light chain (NfL): Progression marker
• TDP-43 in CSF: Disease-specific
• Poly-GA in CSF: C9orf72-specific
• pTDP-43 in plasma: Phosphorylated TDP-43

See Also

• [ALS-FTD Unified Pathway](/mechanisms/als-ftd-unified-pathway)
• [C9orf72 Hexanucleotide Repeat Expansion](/mechanisms/c9orf72-hexanucleotide-repeat-expansion-als-ftd)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [RNA Toxicity](/mechanisms/rna-toxicity)
• [Stress Granule Homeostasis in ALS-FTD](/mechanisms/stress-granule-homeostasis-als-ftd)
• [ALS Pathway](/mechanisms/als-pathway)
• [FTD Pathway](/mechanisms/frontotemporal-dementia-pathway)
• [C9orf72 Gene](/genes/c9orf72)
• [TARDBP Gene](/genes/tardbp)
• [FUS Gene](/genes/fus)

External Links

• [ALS Genetics Database](https://alsod.iop.kcl.ac.uk/)
• [Genetics Home Reference: C9orf72](https://ghr.nlm.nih.gov/gene/C9orf72)
• [International Alliance for ALS/FTD Research](https://www.alsthealliance.org/)

References

[Renton AE, et al. A hexanucleotide repeat expansion in C9orf72 causes ALS and FTD (2011)](https://pubmed.ncbi.nlm.nih.gov/21944779/)

[DeJesus-Hernandez M, et al. Mutations in C9orf72 cause familial ALS with or without FTD (2011)](https://pubmed.ncbi.nlm.nih.gov/21944778/)

[Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and ALS (2006)](https://pubmed.ncbi.nlm.nih.gov/17023659/)

[Strong MJ, et al. Amyotrophic lateral sclerosis frontotemporal spectrum disorder (2017)](https://pubmed.ncbi.nlm.nih.gov/28541283/)

[Ringholz GM, et al. Prevalence and nature of frontotemporal dementia in ALS (2005)](https://pubmed.ncbi.nlm.nih.gov/16247028/)

[Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide repeat proteins (2013)](https://pubmed.ncbi.nlm.nih.gov/23931953/)

[Zhang K, et al. The Drosophila model of C9orf72-hexanucleotide-repeat-dependent neurodegeneration (2015)](https://doi.org/10.1016/j.neuron.2015.10.030)

[Boeve BF, et al. Frontotemporal dementia and ALS: The clinical and pathological continuum (2022)](https://pubmed.ncbi.nlm.nih.gov/35149567/)